Aptamer applications for targeted cancer therapy.

Aptamers are single-stranded DNA or RNA oligonucleotides that assume specific 3D structures and bind to target molecules with high affinity. The unique specificity of aptamers has made them attractive agents for targeted cancer therapy. Aptamers have been developed against a variety of cancer targets, including extracellular ligands and cell surface proteins. In addition, aptamers have been incorporated into novel constructs involving siRNAs, chemotherapeutic agents, cell toxins and nanoparticles, in which they function as delivery agents for therapeutic cargo. In this article, we review recent developments in the use of aptamers for targeted cancer therapy, particularly focusing on novel applications of aptamers targeting the cell surface.

[1]  Ying-Fon Chang,et al.  Tenascin-C Aptamers Are Generated Using Tumor Cells and Purified Protein* , 2001, The Journal of Biological Chemistry.

[2]  Weihong Tan,et al.  Identification of liver cancer-specific aptamers using whole live cells. , 2008, Analytical chemistry.

[3]  Xiaoling Zhang,et al.  Molecular Assembly of an Aptamer–Drug Conjugate for Targeted Drug Delivery to Tumor Cells , 2009, Chembiochem : a European journal of chemical biology.

[4]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[5]  B. Sullenger,et al.  In vivo selection of tumor-targeting RNA motifs , 2009, Nature chemical biology.

[6]  Robert Langer,et al.  Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. , 2007, Biomaterials.

[7]  Anton P. McCaffrey,et al.  Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors , 2009, Nature Biotechnology.

[8]  Gerhard Ziemer,et al.  CELL-SELEX: Novel Perspectives of Aptamer-Based Therapeutics , 2008, International journal of molecular sciences.

[9]  S. Barth,et al.  Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. , 2008, Current cancer drug targets.

[10]  B. Sullenger,et al.  RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  C. Ferreira,et al.  DNA Aptamers That Bind to MUC1 Tumour Marker: Design and Characterization of MUC1-Binding Single-Stranded DNA Aptamers , 2006, Tumor Biology.

[12]  A. Perkins,et al.  Radiolabelled aptamers for tumour imaging and therapy. , 2007, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[13]  Weihong Tan,et al.  Molecular Recognition of Small‐Cell Lung Cancer Cells Using Aptamers , 2008, ChemMedChem.

[14]  Weihong Tan,et al.  Cell-specific aptamer probes for membrane protein elucidation in cancer cells. , 2008, Journal of proteome research.

[15]  Andrew D. Ellington,et al.  Aptamer mediated siRNA delivery , 2006, Nucleic acids research.

[16]  Mark W Dewhirst,et al.  Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer. , 2008, The Journal of surgical research.

[17]  H. Schluesener,et al.  Systematic Evolution of a DNA Aptamer Binding to Rat Brain Tumor Microvessels , 2001, The Journal of Biological Chemistry.

[18]  Kemin Wang,et al.  Selection of aptamers for molecular recognition and characterization of cancer cells. , 2007, Analytical chemistry.

[19]  D. Shangguan,et al.  Aptamer Directly Evolved from Live Cells Recognizes Membrane Bound Immunoglobin Heavy Mu Chain in Burkitt's Lymphoma Cells*S , 2007, Molecular & Cellular Proteomics.

[20]  J. Grande,et al.  Involvement of RNA helicases p68 and p72 in colon cancer. , 2007, Cancer research.

[21]  Weihong Tan,et al.  Applications of aptamers in cancer cell biology. , 2008, Analytica chimica acta.

[22]  Andrew D Ellington,et al.  Aptamer:toxin conjugates that specifically target prostate tumor cells. , 2006, Cancer research.

[23]  Ying Li,et al.  Aptamers evolved from cultured cancer cells reveal molecular differences of cancer cells in patient samples. , 2007, Clinical chemistry.

[24]  L. Stalpers,et al.  Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma. , 2009, European journal of cancer.

[25]  L. Gold,et al.  A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. M. Healy,et al.  Complex target SELEX. , 2008, Accounts of chemical research.

[27]  J. Gariépy,et al.  Phototoxic aptamers selectively enter and kill epithelial cancer cells , 2008, Nucleic acids research.

[28]  Weihong Tan,et al.  DNA aptamer–micelle as an efficient detection/delivery vehicle toward cancer cells , 2009, Proceedings of the National Academy of Sciences.

[29]  L. Kèlland,et al.  Discovery and development of anticancer aptamers , 2006, Molecular Cancer Therapeutics.

[30]  Robert Langer,et al.  Nanotechnology and Aptamers: Applications in Drug Delivery , 2022 .

[31]  Siqing Shan,et al.  Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  E. Spicer,et al.  The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. , 2008, Cancer research.

[33]  Sung Ho Ryu,et al.  A Nucleolin-Targeted Multimodal Nanoparticle Imaging Probe for Tracking Cancer Cells Using an Aptamer , 2010, Journal of Nuclear Medicine.

[34]  Bertrand Tavitian,et al.  Neutralizing Aptamers from Whole-Cell SELEX Inhibit the RET Receptor Tyrosine Kinase , 2005, PLoS biology.

[35]  John O Trent,et al.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. , 2009, Experimental and molecular pathology.

[36]  Ying-Fon Chang,et al.  Tumor targeting by an aptamer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  Robert Langer,et al.  Superparamagnetic Iron Oxide Nanoparticle-Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy , 2011 .

[38]  B. Tavitian,et al.  Differential SELEX in Human Glioma Cell Lines , 2009, PloS one.

[39]  Yong Wang,et al.  Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras , 2006, Nature Biotechnology.

[40]  D. S. Coffey,et al.  Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. , 2002, Cancer research.

[41]  Robert Langer,et al.  Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. , 2007, Nano letters.

[42]  Weihong Tan,et al.  Selective photothermal therapy for mixed cancer cells using aptamer-conjugated nanorods. , 2008, Langmuir : the ACS journal of surfaces and colloids.

[43]  M. Hung,et al.  Nuclear Translocation of the Epidermal Growth Factor Receptor Family Membrane Tyrosine Kinase Receptors , 2009, Clinical Cancer Research.

[44]  B. Sullenger,et al.  Developing aptamers into therapeutics. , 2000, The Journal of clinical investigation.

[45]  A. Ellington,et al.  Directed evolution of gold nanoparticle delivery to cells. , 2010, Chemical communications.

[46]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[47]  J. Richie,et al.  Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Robert Langer,et al.  Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles , 2008, Proceedings of the National Academy of Sciences.

[49]  R. Buhmann,et al.  Aptamers—basic research, drug development, and clinical applications , 2005, Applied Microbiology and Biotechnology.

[50]  Yoshikazu Nakamura,et al.  Selection of RNA aptamers against recombinant transforming growth factor-beta type III receptor displayed on cell surface. , 2006, Biochimie.

[51]  Omid C Farokhzad,et al.  Co‐Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle–Aptamer Bioconjugates , 2007, ChemMedChem.

[52]  Ralf Janknecht,et al.  Synergism between p68 RNA helicase and the transcriptional coactivators CBP and p300 , 2003, Oncogene.

[53]  Robert Langer,et al.  An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. , 2006, Angewandte Chemie.

[54]  T. Mccauley,et al.  Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. , 2007, Cancer research.

[55]  K. Thompson,et al.  Pharmacokinetics and Biodistribution of Novel Aptamer Compositions , 2004, Pharmaceutical Research.